Boehringer Ingelheim and IBM collaborate to advance generative AI and foundation models for therapeutic antibody development Read more
AbbVie Announces FDA and EMA Updates for Epcoritamab (EPKINLY/TEPKINLY) for the Treatment of Relapsed/Refractory Follicular Lymphoma Read more
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma Read more
Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development Read more
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases Read more
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity Read more
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Read more